Cancer-Focused Medivir Licenses AMR Centre Promising Superbug Assets

06 Oct 2017

• By Sten Stovall

Medivir has licensed to the UK's AMR Centre exclusive worldwide rights to its superbug MBLI program in return for a share of eventual sales from generated therapies.

Klebsiella — AMRC Will Develop Compounds From Medivir’s Anti-Superbug MBLI Program • Source: Shutterstock

Sweden-based Medivir – which in October 2016 decided to only focus on oncology R&D – is divesting its research stage metallo-β-lactamase inhibitor (MBLI) program to the UK's AMR Centre Ltd in return for a proportion of future sales from antimicrobials produced.

The MBLI program is aimed at tackling the threat posed by NDM-1 and other metallo-β-lactamases, enzymes that make bacteria resistant...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

25 Jul 2025

• By Jessica Merrill

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

25 Jul 2025

• By Joseph Haas, Lisa Takagi, and Manas Mishra

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

24 Jul 2025

• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.